Received Sep 5, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
Late second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in an unspecified number of patients who did not receive Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (patients received 1st dose of vaccine between AUG-2023 and AUG-2024). On an unknown date, the patients did not receive the 2nd dose of Shingrix. The patient experienced incomplete course of vaccination (Verbatim: Late second dose). The outcome of the incomplete course of vaccination was not applicable. Additional Information: GSK Receipt Date: 25-AUG-2025 Pharmacist called to report that might be like five patients over 65 years of age, between male and female that were administered with a first dose of Shingrix vaccine between AUG-2023 and AUG-2024. The reporter wanted to know do they need to revaccinate or restart the vaccination schedule, was there any percentage drop on effectiveness. No specific vaccination date or details, patient demographics and further information were provided. The vaccine administration facility was the same as primary reporter. Till the time of reporting, the patients did not receive 2nd dose of Shingrix, which led to an incomplete course of vaccination.; Sender's Comments: US-GSK-US2025109347:same reporter, different patient US-GSK-US2025109352:same reporter, different patient